RE:PanCANThe precision promise trial made sense at the time because.
panCan was allowing access to their many locations across the USA. All with in- place trial protocols.
Most importantly they were going to allow existing in- place trial data as the control arm.
Meaning 1/2 the number of patients required & minimum 1/2 the time.
They were going to accept any and all standard of care as comparables. That being to determine improvement if efficacy or not.
No need to subject xxx number of sick & dying people to a trial with placebo medicine to prove a point.
great opportunity!
faster & well managed trial.
no blinding of data, giving real-time results.
afterall, pancreatic cancer victims don't live very long.
So, to reiterate :
based on the inplace results from Goblet , Pela / Onc was chosen to be part if a trial. " news pending within 90 days"
That 90 days came & went. Regrettably PanCan cancelled ALL programs going forward.
The precision promise never got it's expected funding from congress,
That news was devastating for onc. They lost credibility (again) , even though not their fault at all.
They lost what was expected to be a well managed clear sailing trial.
Now?
We wait to see what & how they recover from this disaster. I call it that, because all considering it is.
now in Roche hands.
I also agree, Roche involvement with the precicion promise was not clear.
i believe it was clear the trial would proceed utilizing Roche tecentriq.